Thursday, December 31, 2009

Subcellular targeting strategies for drug design and delivery

Nature Reviews Drug Discovery 9, 29-42 (January 2010) | doi:10.1038/nrd2897

Lawrence Rajendran , Hans-Joachim Kn|[ouml]|lker & Kai Simons  

Keywords: drug targets, drug design strategies,  bioavailability,  tissue targeting, specific intracellular compartments.

Tuesday, December 29, 2009

Molecular diagnostics: techniques and applications for the clinical laboratory

Book review.

Wayne Grody, UCLA School of Medicine, Los Angeles, CA, USA Professor Divisions of Medical Genetics and Molecular Pathology Departments of Path. & Lab. Medicine, Pediatrics, and Human Genetics UCLA School of Medicine Los Angeles, CA 90095-1732
Robert Nakamura, Scripps Clinic, La Jolla, CA, U.S.A.
Frederick Kiechle, Medical Director, Clinical Pathology Department of Pathology Pathology Consultants of South Broward Memorial Healthcare System
Charles Strom, Medical Director, Genetic Testing Center Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA, U.S.A. s

Hardbound, 736 pages, publication date: DEC-2009
ISBN-13: 978-0-12-369428-7
ISBN-10: 0-12-369428-0
Imprint: ACADEMIC PRESS

In Vivo Fluorescent Detection of Fe-S Clusters Coordinated by Human GRX2

Kevin G. Hoff124,Stephanie J. Culler14Peter Q. Nguyen2Ryan M. McGuire3Jonathan J. Silberg23, and Christina D. Smolke1
1 Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E. California Boulevard, Mail Code 210-41, Pasadena, CA 91125, USA
2 Department of Biochemistry and Cell Biology, Rice University, 6100 Main Street, MS 140, Houston, TX 77005, USA
3 Department of Bioengineering, Rice University, 6100 Main Street, MS 140, Houston, TX 77005, USA

Keywords: Fe-S cluster biosynthesis, fluorescent approach, 2Fe2S clusters, Venus fluorescent protein, glutaredoxin 2 (GRX2), ISCU, NFS1. 

Splitting Fluorescent Protein Helps Image Clusters in Live Cells

AZoM.com Pty.Ltd


Posted December 24th, 2009


Keywords: Iron-sulfur clusters, Friedreich's ataxia, sideroblastic anemia, myopathy, fluorescent protein, GRX2, iron-sulfur irregularities, American Heart Association, Friedreich's Ataxia Research Alliance, Robert A. Welch Foundation.

Friday, December 25, 2009

A structural and functional homolog supports a general role for frataxin in cellular iron chemistry

Communication:

Chem. Commun.2010, DOI: 10.1039/b911975b

Wenbin Qi and J. A. Cowan

Keyword:  Bacillus subtilis,  YdhG, frataxin family, iron homeostasis.

Tuesday, December 22, 2009

Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

This study is currently recruiting participants.
Verified by Penwest Pharmaceuticals Co., December 2009
First Received: December 17, 2009   Last Updated: December 18, 2009   History of Changes
Sponsor:
Penwest Pharmaceuticals Co.
Information provided by:
Penwest Pharmaceuticals Co.
ClinicalTrials.gov Identifier:
NCT01035671



Condition Intervention Phase
Friedreich's Ataxia
Drug: alpha-tocopherolquinone (A0001)
Drug: placebo
Phase II

Sunday, December 20, 2009

Age and Dietary Iron Affect Expression of Genes Involved in Iron Acquisition and Homeostasis in Young Pigs.

J Nutr. 2009 Dec 16. [Epub ahead of print]

Department of Animal Science, North Carolina State University, Raleigh, NC 27695-7621.

Highlight:  "frataxin decreased with age of the animal", " the expression of some genes examined in this study was affected by age".

Saturday, December 19, 2009

Coenzyme q10 in neuromuscular and neurodegenerative disorders.

Current drug targets. 2010 Jan;11(1):111-21.

Department of Neuroscience, Neurological Clinic, University of Pisa, Italy, Via Roma 67, 56126 Pisa, Italy

Keywors:  Coenzyme Q10 (CoQ10, or ubiquinone), electron transport chain, oxidative phosphorylation, cellular antioxidant protection, energy metabolism, antioxidant status, neuromuscular and neurodegenerative disorders, idebenone,  mitochondrial disorders, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, clinical practice.

Wednesday, December 16, 2009

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study

Pieter Stolk , Harald E Heemstra , Hubert GM Leufkens , Brigitte Bloechl-Daum and Eibert R Heerdink

Orphanet Journal of Rare Diseases 2009, 4:27doi:10.1186/1750-1172-4-27
Published: 14 December 2009

OPEN ACCESS

Background

Regulators and payers have to strike a balance between the needs of the patient and the optimal allocation of resources. Drugs indicated for rare diseases (orphan medicines) are a special group in this context because of their often high per unit costs. Our objective in this pilot study was to determine, for drugs used in an outpatient setting, how utilisation of centrally authorised drugs varies between countries across a selection of EU member states.

Methods
We randomly selected five orphan medicines and nine other drugs that were centrally authorised in the European Union between January 2000 and November 2006. We compared utilisation of these drugs in six European Union member states: Austria, Denmark, Finland, Portugal, The Netherlands, and Sweden. Utilisation data were expressed as Defined Daily Doses per 1000 persons per year. Variability in use across countries was determined by calculating the relative standard deviation for the utilisation rates of individual drugs across countries.

Results
No association between orphan medicine status and variability in use across countries was found (P=0.52). Drugs with an orphan medicine status were more expensive and had a higher innovation score than drugs without an orphan medicine status.

Conclusions
The results show that the variability in use of orphan medicines in the different health care systems of the European Union appears to be comparable to the other newly authorised drugs that were included in the analysis. This means that, although strong heterogeneity in access may exist, this heterogeneity is not specific for drugs with an orphan status.

Full Text pdf

Tuesday, December 15, 2009

Epigenetics specialists plan to edit the 'book of life'

FierceBiotech Research Newsletter, December 15, 2009

Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program

Download and print (PDF)

Iron binding activity in yeast frataxin entails a trade off with stability in the α1/β1 acidic ridge region

Biochem. J. (2009) Immediate Publication, doi:10.1042/BJ20091612

Ana R. Correia, Tao Wang, Elizabeth A. Craig and Cláudio M. Gomes.
Instituto Tecnologia Química e Biológica, Oeiras 2785-572, Portugal.

Keywords: Frataxin, Friedreich’s ataxia (FRDA), progressive ataxia, cardiomyopathy, Fe-S assembly, Isu, functional regions, α1/β1 acidic ridge, β-sheet surface, iron binding region.

Full text pdf

Human ISCA1 Interacts with IOP1/NARFL and Functions in Both Cytosolic and Mitochondrial Iron-Sulfur Protein Biogenesis

Daisheng Song, Zheng Tu, Frank S. Lee.
From the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Keywords: Iron-sulfur proteins,  IscA,  isc (iron-sulfur cluster) operon,  IscA1,  succinate dehydrogenase,  mitochondrial aconitase, cytosolic aconitase, IOP1 (iron-only hydrogenase-like protein 1)/NARFL (nuclear prelamin A recognition factor-like).

Sunday, December 13, 2009

Clinical measures of dysarthria in Friedreich Ataxia

Movement Disorders, Early View (Articles online in advance of print),Published Online: 11 Dec 2009

Arunjot Singh, MS, Elizabeth Epstein, BA, Lauren M. Myers, BA, Jennifer M. Farmer, MS, David R. Lynch, MD, PhD
 Departments of Neurology and Pediatrics, University of Pennsylvania School of Medicine and The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

Keywords: ataxia, sensory neuron, dysarthria, balance, clinical trial, Friedreich Ataxia (FA), speech, therapeutic monitoring.

AF4 Is a Critical Regulator of the IGF-1 Signaling Pathway during Purkinje Cell Development

The Journal of Neuroscience, December 9, 2009, 29(49):15366-15374; doi:10.1523/JNEUROSCI.5188-09.2009

Emmanuelle Bitoun,1,2 * Mattéa J. Finelli,1,2 * Peter L. Oliver,1,2 Sheena Lee,1 and Kay E. Davies1,2
1Medical Research Council Functional Genomics Unit, and 2Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, United Kingdom

 Keywords:  insulin-like growth factor 1 (IGF-1), cerebellar ataxia,  neuronal cell death, targeted for therapy,  Purkinje cell (PC) death, cerebellum, transcriptional cofactor.

Friday, December 11, 2009

Novel Synchrotron-Based Analyses of Metal Pathology in Friedreich’s Ataxia

University of Saskatchewan Library,  Electronic Theses & Dissertations
Document Type Thesis

Popescu, Bogdan Florin GH.

Keywords: Copper, Iron, Zinc, Rapid Scanning X-ray Fluorescence Mapping, Synchrotron, Brain, Metals, Neurodegeneration, Friedreich's ataxia.

Full text pdf

Thursday, December 10, 2009

The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia.

J Mol Med. 2009 Dec 9.

Richardson DR, Huang ML, Whitnall M, Becker EM, Ponka P, Suryo Rahmanto Y.


Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, Blackburn Building (D06), University of Sydney, Sydney, NSW, 2006, Australia, d.richardson@med.usyd.edu.au.

Keywords: Friedreich's ataxia, cardio- and neurodegenerative disease, frataxin, mitochondrial iron-overload, transferrin receptor-1 upregulation, ferritin, ferroportin1, mitoferrin2, iron-sulfur cluster (ISC), mitochondrial ferritin, compensatory alterations.

Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients

Gene Expression Omnibus, Series GSE11204
Experiment type Expression profiling by array, Public on Dec 08, 2009

Keywords: Friedreich's ataxia; frataxin; mitochondrial DNA damage; nuclear DNA damage; genotoxic stress

Wednesday, December 9, 2009

A Wireless Brain-Machine Interface for Real-Time Speech Synthesis

"Perhaps the most debilitating aspect of profound paralysis due to accident, stroke, or disease is loss of the ability to speak. The loss of speech not only makes the communication of needs to caregivers very difficult, but it also leads to profound social isolation of the affected individual."


PLoS ONE 4(12): e8218. doi:10.1371/journal.pone.0008218

OPEN ACCESS

Frank H. Guenther1,2*, Jonathan S. Brumberg1,3, E. Joseph Wright3, Alfonso Nieto-Castanon4, Jason A. Tourville1, Mikhail Panko1, Robert Law1, Steven A. Siebert3, Jess L. Bartels3, Dinal S. Andreasen3,5, Princewill Ehirim6, Hui Mao7, Philip R. Kennedy3

1 Department of Cognitive and Neural Systems and Sargent College of Health and Rehabilitation Sciences, Boston University, Boston, Massachusetts, United States of America, 2 Division of Health Sciences and Technology, Harvard University-Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, 3 Neural Signals Inc., Duluth, Georgia, United States of America, 4 StatsANC LLC, Buenos Aires, Argentina, 5 Georgia Tech Research Institute, Marietta, Georgia, United States of America, 6 Gwinnett Medical Center, Lawrenceville, Georgia, United States of America, 7 Emory Center for Systems Imaging, Emory University Hospital, Atlanta, Georgia, United States of America

Abstract
Background: Brain-machine interfaces (BMIs) involving electrodes implanted into the human cerebral cortex have recently been developed in an attempt to restore function to profoundly paralyzed individuals. Current BMIs for restoring communication can provide important capabilities via a typing process, but unfortunately they are only capable of slow communication rates. In the current study we use a novel approach to speech restoration in which we decode continuous auditory parameters for a real-time speech synthesizer from neuronal activity in motor cortex during attempted speech.

Methodology/Principal Findings: Neural signals recorded by a Neurotrophic Electrode implanted in a speech-related region of the left precentral gyrus of a human volunteer suffering from locked-in syndrome, characterized by near-total paralysis with spared cognition, were transmitted wirelessly across the scalp and used to drive a speech synthesizer. A Kalman filter-based decoder translated the neural signals generated during attempted speech into continuous parameters for controlling a synthesizer that provided immediate (within 50 ms) auditory feedback of the decoded sound. Accuracy of the volunteer's vowel productions with the synthesizer improved quickly with practice, with a 25% improvement in average hit rate (from 45% to 70%) and 46% decrease in average endpoint error from the first to the last block of a three-vowel task.

Conclusions/Significance: Our results support the feasibility of neural prostheses that may have the potential to provide near-conversational synthetic speech output for individuals with severely impaired speech motor control. They also provide an initial glimpse into the functional properties of neurons in speech motor cortical areas.

Full text pdf

Supplementation with the reduced form of Coenzyme Q10 decelerates phenotypic characteristics of senescence and induces a peroxisome proliferator-activated receptor- gene expression signature in SAMP1 mice

Molecular Nutrition & Food Research
Received: 4 April 2009; Revised: 10 June 2009; Accepted: 30 June 2009.

Constance Schmelzer 1, Hiroshi Kubo 2, Masayuki Mori 3, Jinko Sawashita 3, Mitsuaki Kitano 2, Kazunori Hosoe 4, Inka Boomgaarden 1, Frank Döring 1 *, Keiichi Higuchi 3


1Institute of Human Nutrition and Food Science, Molecular Prevention, Christian-Albrechts-University of Kiel, Kiel, Germany
2Kaneka Corporation, Frontier Biochemical and Medical Research Laboratories, Takasago, Hyogo, Japan
3Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
4Kaneka Corporation, Functional Food Ingredients Division, Osaka, Japan

Keywords:  CoQ10, gene expression, inflammation, lipid metabolism, peroxisome proliferator-activated receptor- alpha, reduced form (Q10H2) coenzyme Q10 (CoQ10),  liver, heart, brain,  kidney,  stronger impact on gene expression, bioavailability, degenerative processes.

Monday, December 7, 2009

Friedreich Ataxia: An Update on Animal Models, Frataxin Function and Therapies

Advances in experimental medicine and biology,   ISSN 0065-2598  CODEN AEMBAP. 2009, vol. 652, pp. 247-261 [15 page(s) (article)

GONZALEZ-CABO Pilar ; VICENTE LLORENS José ; PALAU Francesc ; MOLTO Maria Dolores ;  

Keywords: Friedreich ataxia ; Frataxin ; Mitochondria ; Iron-sulfur clusters ; Oxidative stress ; Oxidative phosphorylation ; Antioxidant therapy ; Iron chelators ; Recombinant human erythropoietin ; Histone deacetylase inhibitors ;

Sunday, December 6, 2009

PGC-1 activation as a therapeutic approach in mitochondrial disease

IUBMB IUBMB Life, 61(11): 1051-1062, 2009

Tina Wenz.
Department of Neurology, University of Miami School of Medicine, Miami, FL 33136, USA

Keywords: Mitochondria,  cellular homeostasis, mitochondrial dysfunction, ATP,  OXPHOS, PGC-1.

Friday, December 4, 2009

Impairment in motor reprogramming in Friedreich ataxia reflecting possible cerebellar dysfunction.

J Neurol. 2009 Dec 3

Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Royal Children's Hospital, 10th Floor, Flemington Road, Parkville, VIC, 3052, Australia.

Keywords: cerebellar and spinocerebellar dysfunction, Friedreich ataxia (FRDA), motor function, cortical pathology, cerebello-cortical projections, , mov6ement execution, movement preparation, age of onset.

Thursday, December 3, 2009

Oxidative Stress Studies in Yeast With a Frataxin Mutant; A Proteomics Perspective

Proteome Res., Just Accepted Manuscript
Publication Date (Web): December 3, 2009
 
Jin-Hee Kim , Miroslav Sedlak , Qiang Gao , Catherine P Riley , Fred Regnier and Jiri Adamec
 
Department of Chemistry, Laboratory of Renewable Resources Engineering, Department of Agricultural and Biological Engineering, Bindley Bioscience Center at Discovery Park, Purdue University, West Lafayette, IN USA 47907

Keywords: Cellular response, Δyfh1 mutant, oxidative stress, iron, mitochondria,  carbonyl groups, reactive oxygen species (ROS), proteomic techniques, protein carbonylation.
 

Absence of aprataxin gene mutations in a Greek cohort with sporadic early onset ataxia and normal GAA triplets in frataxin gene.

Neurol Sci. 2009 Dec 2.

Laboratory of Neurogenetics, Neuroscience Unit, Department of Neurology, Faculty of Medicine, University of Thessalia, Larissa, Greece.

Keywords: Phenotype, aprataxin gene mutation,  GAA expansion,  frataxin gene, exons, flanking intronic sequences, cerebellar ataxia, point mutation, Friedreich ataxia.

A neurite quality index and machine vision software for improved quantification of neurodegeneration

BioTechniques, Vol. 47, No. 6, December 2009, pp. iii–viii

Peggy L. Romero1, Ted Miller2, and Arman M. Garakani2
1Sirtris, A GSK Company, Cambridge, MA, USA
2Reify Corporation, Saratoga, CA, USA
 
Keywords: neurodegradation in dorsal root ganglion cultures,  model for neurodegenerative diseases, quantify neuroprotection, neurite quality index (NQI),  neurosight,  vision-based method, SIRT1, resveratrol, nicotinamide adenine dinucleotide (NAD), axons.
 
Full text pdf

Wednesday, December 2, 2009

Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer

Curr Genomics. 2009 June; 10(4): 281–293. doi: 10.2174/138920209788488517.

E Kirches*

Department of Neuropathology, Otto-von-Guericke University, Magdeburg, Germany

OPEN ACCESS

.../...
3. OTHER NUCLEAR-ENCODED MITOCHONDRIAL PROTEINS DISCUSSED IN CANCER
3.1. Does Frataxin Play an Inhibiting Role in ROS-Mediated Tumorigenesis ?
Friedreich’s ataxia is a severe neurodegenerative disease of adulthood, often accompanied by cardial hypertrophy and usually leading to the patient’s death within 15 years. It is inherited as a recessive autosomal trait, caused by an intronic GAA trinucleotid expansion in the frataxin gene, which switches off transcription of the affected allele [55]. Frataxin is a mitochondrial protein, which is suggested to be involved in iron homeostasis in the mitochondria, since a reduced amount of the protein in patients with the intragenic trinucleotide expansion leads to intramitochondrial iron deposits. Although the details of frataxin function are currently a matter of debate, these deposits may indicate an insufficient transport of iron to the sites of iron-sulfur cluster biogenesis by frataxin [56-59], which in turn may hamper the incorporation of correctly iron-loaded Fe/S-clusters into various mitochondrial proteins, such as the Fe/S-containing ETC complexes. In cell cultures, frataxin inactivation was shown to result in ETC inhibition, as demonstrated by a diminished mitochondrial membrane potential, decreased O2-consumption and decreased oxidative ATP synthesis. Frataxin dysfunction may lead to an inhibition of mitochondrial energy metabolism. On the other hand, a dysfunction of ETC complexes, as well as deposits of free iron (by Fenton reaction) can cause enhanced generation of ROS in the mitochondrial matrix and in the intermembrane space. Oxidative stress is thought to further damage ETC complexes and other redox-sensitive proteins, such as the Krebs cycle enzyme aconitase. This oxidative stress component may further inhibit intermediary metabolism and oxidative ATP synthesis.

Ristow and colleagues analyzed for the first time a potential tumor suppressing function of frataxin in cell culture and animal models, although patients suffering from Friedreich’s ataxia are in no way prone to a higher tumor burden. The idea behind this work was a potential connection between the antioxidative properties of frataxin and ROS-mediated tumorigenesis. The authors analyzed this topic initially in murine 3T3L1 cells, which had been transfected with either a vector expressing human frataxin or a control construct [60]. Both cell clones were exposed to culture conditions with artificially enhanced ROS production. The cells overexpressing frataxin exhibited a significantly lower number of anchorage-independent foci in the culture dishes and the rate of colony formation in soft agar assays was significantly lower, indicating that frataxin protected the cells from ROS-induced transformation into a tumor phenotype. This was further supported by the observation that only cells from the anchorage-independent foci were able to induce tumor growth when xenografted to nude mice.

While oxidative stress in frataxin-deficient patients with Friedreich’s ataxia may be due to the disturbed synthesis of Fe/S-clusters and mitochondrial iron deposits, it is less obvious as to how enforced overexpression of frataxin in normal cells may protect them against ROS. The authors explained the protective effect by the observed increase in glutathione peroxidase (GPx) activity and in reduced thiols. GPx and the reduced form of glutathione play an important role in the detoxification of H2O2, which is built as a product of the SOD- (superoxide dismutase) reaction. Superoxide dismutase 2 (SOD2) is a mitochondrial enzyme, which detoxifies superoxide radicals, released mainly from ETC complexes I and III into the mitochondrial matrix.

In a next step, the authors investigated the potential tumor suppressing effect of enforced frataxin expression in the colon cancer lines MIP101, DLD2 and HT29, which lack endogenous expression of the protein. Mitochondrial oxidative metabolism was enhanced in the transfected cells, as could be shown by an increase of mitochondrial membrane potential, cellular respiration and ATP content, as well as aconitase activity. Increased aconitase activity may be explained in part by decreased oxidative stress. Again, the frataxin cells exhibited a lower colony formation rate in soft agar essays and a lower rate of tumor growth after xenotransplantation to nude mice [61]. The most direct evidence for a role of frataxin in carcinogenesis was reported by the same group using targeted hepatic disruption of frataxin expression in mice. The animals had reduced life spans and developed multiple hepatic tumors, in which high apoptotic and mitotic (Ki-67) indices were observed [62]. The liver specimen showed elevated levels of thiobarbituric-acid reactive substances (TBARS), a marker of lipid peroxidation, and elevated levels of oxidized glutathione, a classical oxidative stress marker. Activities of those mitochondrial enzymes, which contain Fe/S-moieties, i.e. aconitase and ETC complexes I, II, III, were reduced. In accordance with an inhibited oxidative metabolism, the ATP content of livers from knock-out animals was decreased.

The authors did not develop a detailed hypothesis regarding the mechanism of liver tumorigenesis, but speculated that an observed reduction in p38-MAP-kinase phosphorylation may play a role, since activation of this type of mitogen activated protein kinase had been discussed earlier as a factor suppressing the formation of hepatic tumors [63, 64]. Although the authors did not discuss this issue, it might be speculated, whether the observed inhibition of SDH (complex II) may participate in tumorigenesis.
 
.../...

Coenzyme Q10 and Neurological Diseases

Pharmaceuticals 2009, 2, 134-149; doi:10.3390/ph203134

OPEN ACCESS


Michelangelo Mancuso *, Daniele Orsucci, Valeria Calsolaro, Anna Choub and Gabriele Siciliano
Department of Neuroscience, Neurological Clinic, University of Pisa, Tuscany, Italy

Abstract: Coenzyme Q10 (CoQ10, or ubiquinone) is a small electron carrier of the mitochondrial respiratory chain with antioxidant properties. CoQ10 supplementation has been widely used for mitochondrial disorders. The rationale for using CoQ10 is very powerful when this compound is primary decreased because of defective synthesis. Primary CoQ10 deficiency is a treatable condition, so heightened “clinical awareness” about this diagnosis is essential. CoQ10 and its analogue, idebenone, have also been widely used in the treatment of other neurodegenerative disorders. These compounds could potentially play a therapeutic role in Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, Friedreich’s ataxia, and other conditions which have been linked to mitochondrial dysfunction. This article reviews the physiological roles of CoQ10, as well as the rationale and the role in clinical practice of CoQ10 supplementation in different neurological diseases, from primary CoQ10 deficiency to neurodegenerative disorders.
Keywords: coenzyme Q10;  idebenone;  mitochondria; mitochondrial diseases; neurodegeneration

Tuesday, December 1, 2009

Can rehabilitation help ataxia?

Neurology, Vol. 73, Issue 22, 1818-1819, December 1, 2009 , EDITORIALS
Susanne M. Morton and Amy J. Bastian

Intensive coordinative training improves motor performance in degenerative cerebellar disease

NEUROLOGY 2009;73:1823-1830

W. Ilg, PhD, M. Synofzik, MD, D. Brötz, S. Burkard, M. A. Giese, PhD and L. Schöls, MD


From the Departments of Cognitive Neurology (W.I., M.A.G.) and Neurodegeneration (M.S., L.S.), Hertie Institute for Clinical Brain Research and Center of Neurology, Tübingen; Institute of Medical Psychology and Behavioral Neurobiology (D.B.), MEG Center, University Tübingen; and Therapy Centre (S.B.), Center of Neurology, University Clinic Tübingen, Germany.

Keywords: cerebellum, motor control, motor learning, physiotherapeutic training, cerebellar degeneration,  clinical ataxia rating scales, individual goal attainment scores, quantitative movement analysis, gait like velocity, lateral sway, intralimb coordination, standard of care, Berg balance score, goal attainment score, ICARS, international cooperative ataxia rating scale, SARA, scale for the assessment and rating of ataxia.

Monday, November 30, 2009

HDAC6 is a target for protection and regeneration following injury in the nervous system.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19599-604. Epub 2009 Nov 2.

Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jaffrey SR, Twiss JL, Ratan RR, Langley B.
Burke Medical Research Institute, 785 Mamaroneck Avenue, White Plains, NY 10605, USA.

Keywords:Central nervous system (CNS) trauma,, neuronal degeneration, axonal degeneration, toxicity, anticancer properties, neuronal protection against oxidative stress,  promotes neurite growth,  HDAC6.


 

Thursday, November 26, 2009

Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

J Nanoneurosci. 2009 Jun 1;1(1):42-55.

Liu G, Men P, Perry G, Smith MA.

Department of Radiology, University of Utah, Salt Lake City, UT 84108, USA.

Keywords: Alzheimer's disease (AD), blood-brain barrier,  nanoparticle-mediated drug delivery,  chelation agents,  iron-associated neurodegenerative diseases, Friedreich's ataxia, Parkinson's disease, Huntington's disease,  Hallervorden-Spatz Syndrome, nanoparticle technology, very early stages of development.

Clinical aspects of coenzyme Q(10): An update.

Nutrition. 2009 Nov 20.

Littarru GP, Tiano L.
Department of Biochemistry, Biology and Genetics, Polytechnic University of the Marche, Ancona, Italy.

Keywords:  Q(10) (CoQ(10)),  in mitochondrial bioenergetics,  antioxidant properties, clinical applications, cardiovascular disease, physical exercise, mitochondrial myopathies, Parkinson's and Huntington's diseases,  Friedreich's ataxia,  preeclampsia in pregnancy. headache symptoms, pediatric and adolescent populations.

Wednesday, November 25, 2009

A theoretical analysis on characteristics of protein structures induced by cold denaturation

J. Chem. Phys. 131, 205102 (2009); doi:10.1063/1.3265985

Published 24 November 2009

Hiraku Oshima, Takashi Yoshidome, Ken-ichi Amano, and Masahiro Kinoshita

Institute of Advanced Energy, Kyoto University, Uji, Kyoto 611-0011, Japan

Keywords:  frataxin, cold denaturation,  morphometric approach, entropy change,  unfolded structures.

Tuesday, November 24, 2009

A Diet Enriched in Polyphenols and Polyunsaturated Fatty Acids, LMN Diet, Induces Neurogenesis in the Subventricular Zone and Hippocampus of Adult Mouse Brain

Journal of Alzheimer's Disease, IOS Press, DOI 10.3233/JAD-2009-1188
Authors


Tony Valente1, Juan Hidalgo2, Irene Bolea1, Bartolomé Ramirez3, Neus Anglés3, Jordi Reguant3, José Ramón Morelló3, Cristina Gutiérrez1, Mercè Boada4, Mercedes Unzeta1

1Departament de Bioquimica i Biologia Molecular, Institut de Neurociències, Facultat de Medicina, Torre M2, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain
2Institut de Neurociències, and Departamento de Biología Celular, Fisiologia, e Inmunología, Facultat de Biociències, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain
3La Morella Nuts SA, Reus, Tarragona, Spain
Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain

Keywords: 129S1/SvImJ mice, adult neurogenesis, diet, hippocampus, olfactory bulb, polyphenols, polyunsaturated fatty acids, several neurodegenerative pathologies, potent antioxidant effect, neurodegenerative diseases.

Full text:  http://iospress.metapress.com/content/91261l2n31q4q797/fulltext.pdf

Polyphenols and Polyunsaturated Fatty Acids Boost the Birth of New Neurons, Study Finds

ScienceDaily (Nov. 24, 2009) — Universitat Autònoma de Barcelona (UAB) researchers have confirmed that a diet rich in polyphenols and polyunsaturated fatty acids, patented as an LMN diet, helps boost the production of the brain's stem cells -neurogenesis- and strengthens their differentiation in different types of neuron cells. read more....

Histone modifications are specifically relocated during gene activation and nuclear differentiation

OPEN ACCESS

Katharina S Heyse , Susanne E Weber and Hans Joachim Lipps

BMC Genomics 2009, 10:554doi:10.1186/1471-2164-10-554
Published: 24 November 2009

Abstract (provisional)

Background
Post-translational histone modifications (PTMs) and their specific distribution on genes play a crucial role in the control of gene expression, but the regulation of their dynamics upon gene activation and differentiation is still poorly understood. Here, we exploit the unique genome organization of ciliates to analyse PTM dynamics during gene activation in the differentiated cell and during nuclear differentiation. In the macronucleus of these cells the DNA is organized into nanochromosomes which represent independent functional units. Therefore ciliated protozoa represent a simplistic model system to analyse the relevance of histone modifications and their localization for gene expression and differentiation.

Results
We analysed the distribution of three PTMs on six individual nanochromosomes, two of which are silenced in the vegetative cell and only activated during sexual reproduction. We show that a specific relocation of these PTMs correlates with gene activation. Moreover, macronuclear-destined sequences in the differentiating macronucleus display a distribution of PTMs which differs significantly from the PTM patterns of actively transcribed genes.

Conclusions
We show for the first time that a relocation of specific histone modifications takes place during activation of genes. In addition, we demonstrate that genes in a differentiating nucleus are characterised by a specific distribution and composition of PTMs. This allows us to propose a mechanistic model about the relevance of PTMs for gene activation, gene silencing and nuclear differentiation. Results described here will be relevant for eukaryotic cells in general.

The complete article is available as a provisional PDF

Monday, November 23, 2009

Complement-Derived Anaphylatoxin C3a Regulates In Vitro Differentiation and Migration of Neural Progenitor Cells

STEM CELLS
Volume 27 Issue 11;Pages 2824-2832
Published Online: 25;Sep;2009
Noriko Shinjyo 1, Anders Ståhlberg 2, Mike Dragunow 3, Milos Pekny 2, Marcela Pekna 1 *1Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
2Center for Brain Repair and Rehabilitation, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
3Department of Pharmacology and The National Research Centre for Growth and Development, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

Keywords: C3a, ERK1/2 phosphorylation, Neural progenitor cells, Neuronal differentiation, Migration, neuroprotection, neurogenesis.

New Discovery About Formation of New Brain Cells

ScienceDaily (Nov. 23, 2009) — The generation of new nerve cells in the brain is regulated by a peptide known as C3a, which directly affects the stem cells' maturation into nerve cells and is also important for the migration of new nerve cells through the brain tissue, reveals new research from the Sahlgrenska Academy published in the journal Stem Cells. (read more)

A Periplasmic Reducing System Protects Single Cysteine Residues from Oxidation

(Related to the previous post, the source paper of the previus news)

Science 20 November 2009, Vol. 326. no. 5956, pp. 1109 - 1111, DOI: 10.1126/science.1179557
Matthieu Depuydt,1 Stephen E. Leonard,2 Didier Vertommen,1 Katleen Denoncin,1 Pierre Morsomme,3 Khadija Wahni,4,5 Joris Messens,4,5 Kate S. Carroll,2 Jean-François Collet1,*

de Duve Institute, Université catholique de Louvain, B-1200 Brussels, Belgium.
2 Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109–1048, USA.
3 Institut des Sciences de la Vie, Université catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium.
4 Department of Molecular and Cellular Interactions, Vlaams Instituut voor Biotechnologie (VIB), Vrije Universiteit Brussel, B-1050 Brussels, Belgium.
5 Structural Biology Brussels, Vrije Universiteit Brussel, B-1050 Brussels, Belgium.

Keywords:  thiol group, cysteine,  disulfide bonds, oxidation,  sulfenic acids, sulfonic acids,  DsbG, DsbC,  thioredoxin-related proteins.

Saving The Single Cysteine: New Antioxidant System Found

Medical News Today, Article Date: 23 Nov 2009 - 1:00 PST
We've all read studies about the health benefits of having a life partner. The same thing is true at the molecular level, where amino acids known as cysteines are much more vulnerable to damage when single than when paired up with other cysteines.  read more....

Keywords: cysteines, new antioxidant system, DsbG, hyperoxidation, antioxidant therapies,

GUÍA PRÁCTICA DE NECESIDADES EDUCATIVAS ESPECIALES

Original book : At a glance: a practical guide to children's special needs

Autor: Viv EAST y Linda EVANS
Traductor: Pablo Manzano
ISBN: 978-84-7112-609-2
Fecha de la edición: 25/11/2009

Keywors: Necesidades Educativas Especiales, Ataxia de Friedreich, Plan Educativo Individualizado (PEI)

Búsqueda y análisis de fármacos en modelos de ataxia de Friedreich

Ros Cantera, Sheila,
Tesis doctoral del Departamento de Genética de la UV.
Editorial: Instituto de Biomedicina de Valencia, CSIC; Universitat de València, Fecha de publicación: 17-Sep-2009

Keywords: Ataxia de Friedreich, Frataxina, Riboflavina, deferiprona, deferoxamina, amrinona, crisina,


Trabajo completo / full text : http://digital.csic.es/bitstream/10261/17120/1/Tesis%20Sheila%20Ros.pdf

Saturday, November 21, 2009

Epigenetic Silencing in Friedreich Ataxia Is Associated with Depletion of CTCF (CCCTC-Binding Factor) and Antisense Transcription

OPEN ACCESS


PLoS ONE 4(11): e7914. doi:10.1371/journal.pone.0007914
Irene De Biase1#, Yogesh K. Chutake1#, Paul M. Rindler1, Sanjay I. Bidichandani1,2*
1 Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America, 2 Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America

Abstract

 

Background

Over 15 inherited diseases are caused by expansion of triplet-repeats. Friedreich ataxia (FRDA) patients are homozygous for an expanded GAA triplet-repeat sequence in intron 1 of the FXN gene. The expanded GAA triplet-repeat results in deficiency of FXN gene transcription, which is reversed via administration of histone deacetylase inhibitors indicating that transcriptional silencing is at least partially due to an epigenetic abnormality.

Methodology/Principal Findings

We found a severe depletion of the chromatin insulator protein CTCF (CCCTC-binding factor) in the 5′UTR of the FXN gene in FRDA, and coincident heterochromatin formation involving the +1 nucleosome via enrichment of H3K9me3 and recruitment of heterochromatin protein 1. We identified FAST-1 (FXN Antisense Transcript – 1), a novel antisense transcript that overlaps the CTCF binding site in the 5′UTR, which was expressed at higher levels in FRDA. The reciprocal relationship of deficient FXN transcript and higher levels of FAST-1 seen in FRDA was reproduced in normal cells via knockdown of CTCF.

Conclusions/Significance

CTCF depletion constitutes an epigenetic switch that results in increased antisense transcription, heterochromatin formation and transcriptional deficiency in FRDA. These findings provide a mechanistic basis for the transcriptional silencing of the FXN gene in FRDA, and broaden our understanding of disease pathogenesis in triplet-repeat diseases.

 Full text (pdf) http://www.plosone.org/article/fetchObjectAttachment.action;jsessionid=F09024199E18C3B55BF5F22C106E7255?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0007914&representation=PDF

Friday, November 20, 2009

Excellent initiative to spread, and promote scientific research on rare diseases

Public Television of Catalunya, TV3, is doing important work through the "Fundació la Marató deTV3" ,this year focuses on rare diseases.



Yeast frataxin mutants display decreased superoxide dismutase activities crucial to promote protein oxidative damage

Free Radical Biology and Medicine, doi:10.1016/j.freeradbiomed.2009.11.010
Verónica Irazustaa, Elia Obisa, Armando Moreno-Cermeñoa, Elisa Cabiscola, Joaquim Ros, a, and Jordi Tamarita, Grup de Bioquímica de l’Estrés Oxidatiu, Departament de Ciències Mèdiques Bàsiques, Facultat de Medicina, Universitat de Lleida, Lleida, Spain.

Keywords: Iron-overload; protein carbonylation; metal-catalyzed oxidation; frataxin; magnesium-binding proteins, Mn-SOD, CuZn-SOD, superoxide dismutase; iron toxicity; Friedreich ataxia

Thursday, November 19, 2009

Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia

This study is currently recruiting participants.

First Received: November 18, 2009   No Changes Posted
Sponsor:
H. Lundbeck A/S
Information provided by:
H. Lundbeck A/S
ClinicalTrials.gov Identifier:
NCT01016366

Wednesday, November 18, 2009

A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood–Brain Barrier and Provides Neuroprotection

The Journal of Neuroscience, November 4, 2009, 29(44):13761-13769; doi:10.1523/JNEUROSCI.4246-09.2009

Hulya Karatas,1 Yesim Aktas,2 Yasemin Gursoy-Ozdemir,1 Ebru Bodur,3 Muge Yemisci,1 Secil Caban,2 Atay Vural,1 Onur Pinarbasli,2 Yilmaz Capan,2 Eduardo Fernandez-Megia,4 Ramon Novoa-Carballal,4 Ricardo Riguera,4 Karine Andrieux,5 Patrick Couvreur,5 and Turgay Dalkara1

1Department of Neurology, Faculty of Medicine and Institute of Neurological Sciences and Psychiatry, 2Department of Pharmaceutical Technology, Faculty of Pharmacy, and 3Department of Biochemistry, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey, 4Departamento de Química Orgánica, Facultad de Química, and Unidad de Resonancia Magnética Nuclear de Biomoléculas Asociada al Consejo Superior de Investigaciones Científicas, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain, and 5Physico-Chimie, Pharmacotechnie, Biopharmacie, Faculté de Pharmacie, Université Paris Sud, UMR Centre National de la Recherche Scientifique 8612, 92296 Chatenay Malabry, France

Keywords:  cross the blood–brain barrier (BBB), nanocarrier system,chitosan nanospheres, caspase-3 inhibitor, Polyethylene glycol-coated nanospheres, intravenously injected,  neuroprotection, efficient penetration, brain delivery,  treatment of CNS disorders.

On Your Last Nerve: Researchers Advance Understanding of Stem Cells

ScienceDaily (Nov. 17, 2009) — Researchers from North Carolina State University have identified a gene that tells embryonic stem cells in the brain when to stop producing nerve cells called neurons. The research is a significant advance in understanding the development of the nervous system, which is essential to addressing conditions such as Parkinson's disease, Alzheimer's disease and other neurological disorders.

Read more ...

Sunday, November 15, 2009

Acute Beta-adrenergic Stimulation does not Alter Mitochondrial Protein Synthesis or Markers of Mitochondrial Biogenesis in Adult Men.

Am J Physiol Regul Integr Comp Physiol. 2009 Nov 11

Robinson MM, Richards JC, Hickey MS, Moore DR, Phillips SM, Bell C, Miller BF.
Colorado State University.

Keywords: peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1alpha), beta-adrenergic receptor (beta-AR) antagonist, skeletal muscle PGC-1alpha expression, mitochondrial biogenesis, whole body protein turnover (WBPT), myofibrillar protein synthesis (MyPS), skeletal muscle mitochondrial protein synthesis (MiPS), mitochondrial biogenic signalling, non-specific beta-AR agonist (isoproterenol (ISO),PGC-1alpha, TFAM, NRF-1, NRF-2, COX, NADHox.

Saturday, November 14, 2009

Frataxin (FXN); histone deacetylase 3 (HDAC3)

SciBX: Science-Business eXchange 2, (2009) | doi:10.1038/scibx.2009.1637.

Kwywords: cell culture, HDAC3, Friedreich's ataxia, neurodegenerative, FXN gene.

Thursday, November 12, 2009

Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression

Gene Therapy (2009) 16, 1292–1299; doi:10.1038/gt.2009.111;
S A Sakowski1, S B Heavener2,5, J S Lunn1, K Fung3, S S Oh1, S K Spratt4, N D Hogikyan2 and E L Feldman1

1Department of Neurology, University of Michigan Medical Center, Ann Arbor, MI, USA
2Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA
3Department of Otolaryngology, University of Western Ontario, London, Ontario, Canada
4Sangamo BioSciences, Inc., Richmond, CA, USA

Keywords:zinc-finger protein (ZFP) transcription factors, adenoviral vectors, Ad-32Ep65-Flag (Ad-p65), VEGF, increase in axon outgrowth, neuroprotective effects, laryngeal nerve (RLN)-crush injury, nerve regeneration, nerve injury, neurodegeneration.

Monday, November 9, 2009

Vascular niche factor PEDF modulates Notch-dependent stemness in the adult subependymal zone

Nature Neuroscience

Published online: 8 November 2009
doi:10.1038/nn.2437
Celia Andreu-Agulló, José Manuel Morante-Redolat, Ana C Delgado & Isabel Fariñas.
About stem cells, neurodegeneration, not specific Friedreich ataxia
Keywords: stem cell microenvironments, regulate self-renewal,  astroglia-like neural stem cells (NSCs), Notch transcriptional activity,  multipotency, Pigment epithelium–derived factor (PEDF), NF-B pathway, N-CoR.
 
Link To Full text: http://www.nature.com/neuro/journal/vaop/ncurrent/full/nn.2437.html

Friday, November 6, 2009

The specificity of neuroprotection by antioxidants

Journal of Biomedical Science 2009, 16:98doi:10.1186/1423-0127-16-98

Published: 5 November 2009

Yuanbin Liu and David R Schubert


Cellular Neurobiology Laboratory, The Salk Institute for Biological Studies,10010 N. Torrey Pines Road, La Jolla, California 92037-1099 USA


OPEN ACCESS

Abstract (provisional)


Background

Reactive oxygen species (ROS) play an important role in aging and age-related diseases such as Parkinson's disease and Alzheimer's disease. Much of the ROS production under conditions of toxic stress is from mitochondria, and multiple antioxidants prevent ROS accumulation. The aim of this study is to examine the specificity of the interaction between the antioxidants and ROS production in stressed cells.

Methods

Using fluorescent dyes for ROS detection and mitochondrial inhibitors of known specificities, we studied ROS production under three conditions where ROS are produced by mitochondria: oxidative glutamate toxicity, state IV respiration induced by oligomycin, and tumor necrosis factor-induced cell death.

Results

We demonstrated that there are at least four mitochondrial ROS-generating sites in cells, including the flavin mononucleotide (FMN) group of complex I and the three ubiquinone-binding sites in complexes I, II and III. ROS production from these sites is modulated in an insult-specific manner and the sites are differentially accessible to common antioxidants.

Conclusions

The inhibition of ROS accumulation by different antioxidants is specific to the site of ROS generation as well as the antioxidant. This information should be useful for devising new interventions to delay aging or treat ROS-related diseases.



Link to full text: http://www.jbiomedsci.com/content/pdf/1423-0127-16-98.pdf

Thursday, November 5, 2009

Auditory Perception in Individuals with Friedreich's Ataxia

Audiol Neurotol 2010;15:229-240 (DOI: 10.1159/000255341)
Gary Rancea, Louise Corbenb, Elizabeth Barkera, Peter Carewa, Donella Chisaria, Meghan Rogersa, Richard Dowella, Saiful Jamaluddina, Rochelle Brysona, Martin B. Delatyckib

aDepartment of Otolaryngology, The University of Melbourne, and
bMurdoch Children's Research Institute, Parkville, Vic., Australia

Keywords: Friedreich's ataxia, Auditory perception, Temporal processing, Speech perception.

Wednesday, November 4, 2009

Auditory plasticity and speech motor learning

Sazzad M. Nasira and David J. Ostrya,
Department of Psychology, McGill University, Montreal, QC, Canada H3A 1B1; and  Haskins Laboratories, New Haven, CT 06511

Edited by Michael M. Merzenich, University of California, San Francisco, CA, and approved September 24, 2009 (received for review June 28, 2009)

OPEN ACCES
 
Abstract


Is plasticity in sensory and motor systems linked? Here, in the context of speech motor learning and perception, we test the idea sensory function is modified by motor learning and, in particular, that speech motor learning affects a speaker's auditory map. We assessed speech motor learning by using a robotic device that displaced the jaw and selectively altered somatosensory feedback during speech. We found that with practice speakers progressively corrected for the mechanical perturbation and after motor learning they also showed systematic changes in their perceptual classification of speech sounds. The perceptual shift was tied to motor learning. Individuals that displayed greater amounts of learning also showed greater perceptual change. Perceptual change was not observed in control subjects that produced the same movements, but in the absence of a force field, nor in subjects that experienced the force field but failed to adapt to the mechanical load. The perceptual effects observed here indicate the involvement of the somatosensory system in the neural processing of speech sounds and suggest that speech motor learning results in changes to auditory perceptual function.

link to full text: http://www.pnas.org/content/early/2009/10/30/0907032106.full.pdf

Researchers Unlock The 'Sound Of Learning' By Linking Sensory And Motor Systems

Medicalnewstoday, Article Date: 04 Nov 2009 - 0:00 PST

Learning to talk also changes the way speech sounds are heard, according to a new study published in Proceedings of the National Academy of Sciences by scientists at Haskins Laboratories, a Yale-affiliated research laboratory. The findings could have a major impact on improving speech disorders. (read more)

Frataxin interacts with Isu1 through a conserved tryptophan in its beta-sheet.

Hum Mol Genet. 2009,  Nov 2.

Leidgens S, De Smet S, Foury F.

Unité de Biochimie Physiologique, Institut des Sciences de la Vie, Université Catholique de Louvain, Croix du Sud 5-15, 1348 Louvain-la-Neuve, Belgium.

Keywords: Friedreich's ataxia, frataxin, iron-sulfur (Fe/S) clusters, Yfh1, Isu1, beta-sheet platform, Q129A, I130A, W131A(F), R141A, low aconitase activity, Gln-129, Trp-131, Arg-141, aromatic side chain.

Monday, November 2, 2009

Iron Deficiency is the Most Common Deficiency Among People

November 02, 2009
http://www.associatedcontent.com/

Keyword: Dr. Timothy Stemmler, Wayne State University, University of Michigan-Dearborn, iron deficiency, Anemia, Parkinson's, Fredreich's Ataxia,  frataxin.

Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia in a study also assessing efficacy via biomarkers

PR-inside.com,
London, November , 02, 2009
 
Keywords: H. Lundbeck A/S, phase IIa clinical studies, project Lu AA24493, safety  and
tolerability,  Friedreich's ataxia,  carbamoylated form of human erythropoietin (EPO), loss of haematopoietic effects,  neuronal damage,

----------------------------------------------------------

Pharmacy Europe,
Latest News, Monday 2nd November 2009

Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO)

---------------------------------------------------------

Reuters.com
Mon Nov 2, 2009 5:10am EST

Lundbeck says expands stroke drug candidate trials

Saturday, October 31, 2009

Whole-body isometric force/torque measurements for functional assessment in neuro-rehabilitation: platform design, development and verification

OPEN ACCESS

Stefano Mazzoleni , Andras Toth , Marko Munih , Jo Van Vaerenbergh , Giuseppe Cavallo , Silvestro Micera , Paolo Dario  and Eugenio Guglielmelli
Journal of NeuroEngineering and Rehabilitation 2009, 6:38doi:10.1186/1743-0003-6-38
Published: 30 October 2009

Abstract (provisional)

Background

One of the main scientific and technological challenges of rehabilitation bioengineering is the development of innovative methodologies, based on the use of appropriate technological devices, for an objective assessment of patients undergoing a rehabilitation treatment. Such tools should be as fast and cheap to use as clinical scales, which are currently the daily instruments most widely used in the routine clinical practice.
Methods

A human-centered approach was used in the design and development of a mechanical structure equipped with eight force/torque sensors that record quantitative data during the initiation of a predefined set of Activities of Daily Living (ADL) tasks, in isometric conditions.
Results

Preliminary results validated the appropriateness, acceptability and functionality of the proposed platform, that has become now a tool used for clinical research in three clinical centres.
Conclusions

This paper presented the design and development of an innovative platform for whole-body force and torque measurements on human subjects. The platform has been designed to perform accurate quantitative measurements in isometric conditions with the specific aim to address the needs for functional assessment tests of patients undergoing a rehabilitation treatment as a consequence of a stroke. The versatility of the system also enlightens several other interesting possible areas of application for therapy in neurorehabilitation, for research in basic neuroscience, and more.

Link to full text: http://www.jneuroengrehab.com/content/pdf/1743-0003-6-38.pdf

Friday, October 30, 2009

Progressive GAA·TTC Repeat Expansion in Human Cell Lines

OPEN ACCESS

Scott Ditch, Mimi C. Sammarco, Ayan Banerjee, Ed Grabczyk*


Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America

Abstract

Trinucleotide repeat expansion is the genetic basis for a sizeable group of inherited neurological and neuromuscular disorders. Friedreich ataxia (FRDA) is a relentlessly progressive neurodegenerative disorder caused by GAA·TTC repeat expansion in the first intron of the FXN gene. The expanded repeat reduces FXN mRNA expression and the length of the repeat tract is proportional to disease severity. Somatic expansion of the GAA·TTC repeat sequence in disease-relevant tissues is thought to contribute to the progression of disease severity during patient aging. Previous models of GAA·TTC instability have not been able to produce substantial levels of expansion within an experimentally useful time frame, which has limited our understanding of the molecular basis for this expansion. Here, we present a novel model for studying GAA·TTC expansion in human cells. In our model system, uninterrupted GAA·TTC repeat sequences display high levels of genomic instability, with an overall tendency towards progressive expansion. Using this model, we characterize the relationship between repeat length and expansion. We identify the interval between 88 and 176 repeats as being an important length threshold where expansion rates dramatically increase. We show that expansion levels are affected by both the purity and orientation of the repeat tract within the genomic context. We further demonstrate that GAA·TTC expansion in our model is independent of cell division. Using unique reporter constructs, we identify transcription through the repeat tract as a major contributor to GAA·TTC expansion. Our findings provide novel insight into the mechanisms responsible for GAA·TTC expansion in human cells.

Link to full text: http://www.plosgenetics.org/article/fetchObjectAttachment.action;jsessionid=1C3EDADDCEC7DDCE3438B379DC71EE00?uri=info%3Adoi%2F10.1371%2Fjournal.pgen.1000704&representation=PDF

Thursday, October 29, 2009

Researchers Find Brain Cell Transplants Help Repair Neural Damage

ScienceDaily (Oct. 29, 2009) — A Swiss research team has found that using an animal's own brain cells (autologous transplant) to replace degenerated neurons in select brain areas of donor primates with simulated but asymptomatic Parkinson's disease and previously in a motor cortex lesion model, provides a degree of brain protection and may be useful in repairing brain lesions and restoring function. (read more)

Neuroprotective effects of blockers for T-type calcium channels

Molecular Neurodegeneration 2009, 4:44doi:10.1186/1750-1326-4-44
Published: 28 October 2009

OPEN ACCESS

Norelle C Wildburger , Avary Lin-Ye , Michelle A Baird , Debin Lei and Jianxin Bao


Abstract
Cognitive and functional decline with age is correlated with deregulation of intracellular calcium, which can lead to neuronal death in the brain. Previous studies have found protective effects of various calcium channel blockers in pathological conditions. However, little has been done to explore possible protective effects of blockers for T-type calcium channels, which forms a family of FDA approved anti-epileptic drugs. In this study, we found that neurons showed an increase in viability after treatment with either L-type or T-type calcium channel antagonists. The family of low-voltage activated, or T-type calcium channels, comprise of three members (Cav3.1, Cav3.2, and Cav3.3) based on their respective main pore-forming alpha subunits: alpha 1G, alpha 1H, and alpha 1I. Among these three subunits, alpha 1H is highly expressed in hippocampus and certain cortical regions. However, T-type calcium channel blockers can protect neurons derived from alpha 1H-/- mice, suggesting that neuroprotection demonstrated by these drugs is not through the alpha 1H subunit. In addition, blockers for T-type calcium channels were not able to confer any protection to neurons in long-term cultures, while blockers of L-type calcium channels could protect neurons. These data indicate a new function of blockers for T-type calcium channels, and also suggest different mechanisms to regulate neuronal survival by calcium signaling pathways. Thus, our findings have important implications in the development of new treatment for age-related neurodegenerative disorders.

Link to full text: http://www.molecularneurodegeneration.com/content/pdf/1750-1326-4-44.pdf

Epilepsy Drugs Could Treat Alzheimer's And Parkinson's

ScienceDaily (Oct. 29, 2009) — Researchers in the USA have discovered a potential new function for anti-epileptic drugs in treating neurodegenerative disorders such as Alzheimer's and Parkinson's disease. The study, published in BioMed Central's open access journal Molecular Neurodegeneration, found that neurons in the brain were protected after treatment with T-type calcium-channel blockers, which are commonly used to treat epilepsy. (read more)

Saturday, October 24, 2009

Video about Physical Therapy in Friedreich ataxia.

Fisio - Atassia di Friedreich - FA

Erythropoietin: a multimodal neuroprotective agent

Nadiya Byts and Anna-Leena Siren

Experimental & Translational Stroke Medicine 2009, 1:4doi:10.1186/2040-7378-1-4
Published: 21 October 2009

OPEN ACCESS

Abstract (provisional)

The tissue protective functions of the hematopoietic growth factor erythropoietin (EPO) are independent of its action on erythropoiesis. EPO and its receptors (EPOR) are expressed in multiple brain cells during brain development and upregulated in the adult brain after injury. Peripherally administered EPO crosses the blood-brain barrier and activates in the brain anti-apoptotic, anti-oxidant and anti-inflammatory signaling in neurons, glial and cerebrovascular endothelial cells and stimulates angiogenesis and neurogenesis. These mechanisms underlie its potent tissue protective effects in experimental models of stroke, cerebral hemorrhage, traumatic brain injury, neuroinflammatory and neurodegenerative disease. The preclinical data in support of the use of EPO in brain disease have already been translated to first clinical pilot studies with encouraging results with the use of EPO as a neuroprotective agent.

The complete article is available as a provisional PDF . CLICK HERE

Direct Fe2+ Sensing by Iron-responsive Messenger RNA·Repressor Complexes Weakens Binding*

October 30, 2009 The Journal of Biological Chemistry, 284, 30122-30128.

1. Mateen A. Khan‡, 2. William E. Walden§, 3. Dixie J. Goss‡,1 and 4. Elizabeth C. Theil¶‖,2

1. From the ‡Department of Chemistry, Hunter College, City University of New York, New York, New York 10065,
2. the §Department of Microbiology and Immunology, University of Illinois, Chicago, Illinois 60612-7334,
3. the ¶Children's Hospital Oakland Research Institute, Oakland, California 94609, and
4. the ‖Department of Nutrition Science and Toxicolology, University of California, Berkeley, California 94720

Keywords: Fe2+, ferritin, mitochondrial aconitase messenger, regulatory proteins (IRPs),iron-induced mRNA translation.

Friday, October 23, 2009

Next generation sequence analysis for mitochondrial disorders

Valeria Vasta , Sarah B Ng , Emily H Turner , Jay Shendure and Si Houn Hahn
Genome Medicine 2009, 1:100doi:10.1186/gm100
Published: 23 October 2009
OPEN ACCESS
Link to full text
Background
Mitochondrial disorders can originate from mutations in one of many nuclear genes controlling the organelle function or in the mitochondrial genome (mitochondrial DNA (mtDNA)). The large numbers of potential culprit genes, together with the little guidance offered by most clinical phenotypes as to which gene may be causative, are a great challenge for the molecular diagnosis of these disorders.

Methods
We developed a novel targeted resequencing assay for mitochondrial disorders relying on microarray-based hybrid capture coupled to next-generation sequencing. Specifically, we subjected the entire mtDNA genome and the exons and intron-exon boundary regions of 362 known or candidate causative nuclear genes to targeted capture and resequencing. We here provide proof-of-concept data by testing one HapMap DNA sample and two positive control samples.

Results
Over 94% of the targeted regions were captured and sequenced with appropriate coverage and quality, allowing reliable variant calling. Pathogenic mutations blindly tested in patients' samples were 100% concordant with previous Sanger sequencing results: a known mutation in Pyruvate dehydrogenase alpha 1 subunit (PDHA1), a novel splicing and a known coding mutation in Hydroxyacyl-CoA dehydrogenase alpha subunit (HADHA) were correctly identified. Of the additional variants recognized, 90 to 94% were present in dbSNP while 6 to 10% represented new alterations. The novel nonsynonymous variants were all in heterozygote state and mostly predicted to be benign. The depth of sequencing coverage of mtDNA was extremely high, suggesting that it may be feasible to detect pathogenic mtDNA mutations confounded by low level heteroplasmy. Only one sequencing lane of an eight lane flow cell was utilized for each sample, indicating that a cost-effective clinical test can be achieved.

Conclusions
Our study indicates that the use of next generation sequencing technology holds great promise as a tool for screening mitochondrial disorders. The availability of a comprehensive molecular diagnostic tool will increase the capacity for early and rapid identification of mitochondrial disorders. In addition, the proposed approach has the potential to identify new mutations in candidate genes, expanding and redefining the spectrum of causative genes responsible for mitochondrial disorders.


................................................................

Focus: Genes targeted for capture and sequencing....Enzymes...FXN,
New variants and mutations identified in the samples..... FXN [Genbank:NM_000144.3]:c.626A>G (p.Asp209Gly) het

The conserved Trp-155 in human frataxin as a hotspot for oxidative stress related chemical modifications

Biochemical and Biophysical Research Communications

Ana R. Correiaa, Saw Y. Owb, Phillip C. Wrightb and Cláudio M. Gomesa, Corresponding Author Contact Information, E-mail The Corresponding Author

aInstituto Tecnologia Química e Biológica, Universidade Nova de Lisboa, 2780-756 Oeiras, Portugal

bDepartment of Chemical and Process Engineering, ChELSI, University of Sheffield, Sheffield S10 2TN, UK

Received 15 October 2009.
Available online 22 October 2009.

Keywords: Friedreich’s Ataxia, Frataxin, Protein Folding, Protein Flexibility, Metallochaperone, Oxidative Stress, Fenton reactions, carbonylation, nitration.

Thursday, October 22, 2009

Students Invite Chemists Everywhere To Help With Orphaned Drugs, Diseases

Medical News Today, 21 Oct 2009

Suppose you had a disease for which there's a proven cure, but nobody makes the drug. Where do you turn?

The Cure for Needy Project (http://www.cureforneedy.org)

Wednesday, October 21, 2009

Redox Control of the Cell Cycle in Health and Disease

Online Ahead of Print: October 21, 2009
Ehab H. Sarsour, Maneesh G. Kumar, Leena Chaudhuri, Amanda L. Kalen, Prabhat C. Goswami, Jurgen Bernhagen, Claudia Castro, Peter M. Chumakov, Tohru Fukai, Fuyuki Ishikawa, Hugo Monteiro, Hasan Mukhtar, Mark Smith, Rhian Touyz. Antioxidants & Redox Signaling. doi:10.1089/ars.2009.2513.

Free Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, Iowa.

Keywords: reactive oxygen species (ROS), second messengers, quiescence (G0),proliferation (G1, S, G2, and M), cancer, wound healing, fibrosis, cardiovascular diseases, diabetes, and neurodegenerative diseases.

Children With Brain-Damage Often Have Cold Feet

Medicalnewstoday, Article Date: 21 Oct 2009

Many wheelchair-using children with neurological disorders have much colder hands and feet than other children, and most receive no special help even though they have had these problems for a long time, is revealed in at thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.
(read more)

Monday, October 19, 2009

Inherited Neuromuscular Diseases (book )

Translation from Pathomechanisms to Therapies
Series: Advances in Experimental Medicine and Biology , Vol. 652

Espinós, Carmen; Felipo, Vicente; Palau, Francesc (Eds.)

2009, XIII, 304 p., Hardcover

ISBN: 978-90-481-2812-9

Keywords: muscular dystrophies, mitochondrial disorders, peripheral neuropathies, spinal muscular atrophy, motoneurone disease, Friedreich ataxia, genetics, neuromuscular disorders, peripheral nervous system, cellular biology, pathomechanisms, therapies and treatments.

Idebenone Appears Safe in Patients With Friedreich's Ataxia: Presented at ANA

Doctor's Guide Publishing Limited.

Presentation title: SNT-MC17/Idebenone to Treat Friedreich's Ataxia: Preliminary Phase 3 Safety Data. Poster T-80]

Keywords: blinded interim safety analysis, Friedreich's ataxia, clinical trial, idebenone, severe events, supraventricular extrasystole, reduced visual acuity, fatigue, anxiety, flatulence/abdominal discomfort, electrocardiograms, vital signs, laboratory test, SNT-MC17, headache, nausea, diarrhoea, vomiting, abdominal pain, upper abdominal pain, fatigue, hypercholesterolaemia, rash, flatulence, pruritus.

Saturday, October 17, 2009

The N-terminus of mature human frataxin is intrinsically unfolded

FEBS Journal, Early View (Articles online in advance of print)
Published Online: 16 Oct 2009
Journal compilation © 2009 Federation of European Biochemical Societies

Filippo Prischi 1 , Clelia Giannini 2 , Salvatore Adinolfi 3 and Annalisa Pastore 3
1 Dipartimento di Biologia Molecolare, University of Siena, Siena, Italy
2 Dipartimento di Chimica Organica ed Industriale, University of Milano, Italy
3 National Institute for Medical Research, MRC, The Ridgeway, London, UK

KEYWORDS: dynamics, Friedreich's ataxia, IUPs, NMR, structure, Frataxin, mitochondrial protein, neurodegenerative disease, globular domain, N-terminal, unfolded, iron-binding.

Friday, October 16, 2009

Scientists Map First Complete Human Epigenome, The Driver Of Gene Expression

Scientists Map First Complete Human Epigenome, The Driver Of Gene Expression
Genetics News From Medical News Today
When scientists mapped the DNA sequence of 3 billion bases in the human genome they uncovered the master blueprint of what makes a human being; now a team in the US has produced a high resolution map of the first complete human epigenome, the driver of gene expression that regulates how all the options offered in the genome are put together to make the unique person that grows in a particular environment.

Thursday, October 15, 2009

Cell's Powerhouses Dismantled: Complete Inventory Of All Proteins In Mitochondria

ScienceDaily (Oct. 15, 2009) — All of life is founded on the interactions of millions of proteins. These are the building blocks for cells and form the molecular mechanisms of life. The problem is that proteins are extremely difficult to study, particularly because there are so many of them and they appear in all sizes and weights. Now, Kris Gevaert from VIB/Ghent University and colleagues from the universities of Freiburg and Bochum have achieved a breakthrough in protein research. Using yeast, they have succeeded in making virtually the complete inventory of all the proteins in the mitochondria, the energy producers found in every cell.



Full text in ScienceDaily : http://www.sciencedaily.com/releases/2009/10/091015123602.htm

alpha-tocopherol beta-Oxidation Localized to Rat Liver Mitochondria

Free Radic Biol Med. 2009 Oct 8

Mustacich DJ, Leonard SW, Patel NK, Traber MG.
Linus Pauling Institute, Oregon State University, Corvallis, OR.

Keywords: dietary supplements, vitamin E (alpha-tocopherol), hepatic metabolism, microsomes, peroxisomes, trolox, alpha-CEHC, "mitochondrial role in alpha-tocopherol metabolism".

Wednesday, October 14, 2009

Cerebellar Contributions to Adaptive Control of Saccades in Humans

The Journal of Neuroscience, October 14, 2009, 29(41):12930-12939; doi:10.1523/JNEUROSCI.3115-09.2009

Minnan Xu-Wilson,1 Haiyin Chen-Harris,1 David S. Zee,2 and Reza Shadmehr1

1Departments of Biomedical Engineering and 2Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205

Keywords: cerebellum, internal feedback correct, saccades, cerebellar damage, dysmetria.

Nutrition, Brain Aging, and Neurodegeneration

The Journal of Neuroscience, October 14, 2009, 29(41):12795-12801; doi:10.1523/JNEUROSCI.3520-09.2009

James Joseph,1 Greg Cole,2 Elizabeth Head,3 and Donald Ingram4

1USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111, 2Geriatric Research, Education and Clinical Centers, Veterans Affairs Medical Center, and Department of Medicine, University of California, Los Angeles, Sepulveda, California 91343, 3University of Kentucky Sanders-Brown Center on Aging, Lexington, Kentucky 40536, and 4Pennington Biomedical Center, Baton Rouge, Louisiana 70808



Unfortunately we all know what is the FA, and these tips are not enough, but they are interesting.

Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)

Official Title: A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.

This study is currently recruiting participants.
Verified by Santhera Pharmaceuticals, October 2009
First Received: October 13, 2009

Sponsored by: Santhera Pharmaceuticals

ClinicalTrials.gov Identifier: NCT00993967

Stress ossidativo ed anomalie citoscheletriche nell’Atassia di Friedreich

Piemonte, Fiorella
Gaeta, Laura Maria
UNIVERSITÀ DEGLI STUDI DI ROMA "TOR VERGATA", FACOLTA' DI MEDICINA, DOTTORATO DI RICERCA IN BIOTECNOLOGIE MEDICHE E MEDICINA MOLECOLARE

Issue Date: 6-Aug-2009

Keywords: Atassia di Friedreich, glutatione, proteine glutationilate, citoscheletro, stress ossidativo, regolazione redox.

Link to full text: http://dspace.uniroma2.it/dspace/bitstream/2108/994/1/TESI+DI+DOTTORATO.pdf

A comparison of three measures of upper limb function in Friedreich ataxia.

J Neurol. 2009 Oct 13.
Corben LA, Tai G, Wilson C, Collins V, Churchyard AJ, Delatycki MB.
Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Flemington Rd, Parkville, VIC, 3052, Australia.

Keywords: Friedreich Ataxia (FRDA), false negative results, upper limb function, the Nine Hole Peg Test (9HPT), Box and Blocks Test (BBT), Jebsen Taylor Hand Function Test (JTHFT),Friedreich Ataxia Functional Composite (FAFC) test, clinical studies, terapeutic trials, age at disease onset, disease duration, Friedreich Ataxia Rating Scale (FARS).

Tuesday, October 13, 2009

Antioxidants and other pharmacological treatments for Friedreich ataxia.

Cochrane Database Syst Rev. 2009 Oct 7;4:CD007791

Kearney M, Orrell RW, Fahey M, Pandolfo M.
General Practice, Irish College of General Practitioners, Dunlavin, County Wicklow, Ireland.

Keywords: Friedreich ataxia, autosomal recessive, neurological disorder, slurred speech, scoliosis, pes cavus, heart abnormalities, antioxidants, controlled trials, international Co-operative Ataxia Rating Scale (ICARS),left ventricular heart mass, magnetic resonance imaging, echocardiography, idebenone.

Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities

Rao Muralikrishna Adibhatla, James Franklin Hatcher, Savita Khanna, Shrinivas K. Kulkarni, Pamela Maher, Cesare Mancuso, Stanley I. Rapoport, Mark Smith, Bobby Thomas, Tatsurou Yagami. Antioxidants & Redox Signaling. -Not available-, ahead of print. doi:10.1089/ars.2009.2668.

Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.Cardiovascular Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.Neuroscience Training Program, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. William S. Middleton Veterans Affairs Hospital, Madison, Wisconsin.

Keywords: Reactive oxygen species (ROS), oxidative phosphorylation, NAD(P)H oxidases, arachidonic acid oxidative metabolism, endogenous antioxidant defenses, Nrf2/ARE, Oxidative stress, lipids, cell death, oxidized phospholipids, 4-hydroxynonenal, 4-oxo-2-nonenal, acrolein, neurodegenerative diseases (AD, ALS, bipolar disorder, epilepsy, Friedreich's ataxia, HD, MS, NBIA, NPC, PD, peroxisomal disorders, schizophrenia, Wallerian degeneration, Zellweger syndrome), CNS traumas (stroke, TBI, SCI), free iron, Fenton reaction, cholesterol, lipid oxidation/peroxidation.

Saturday, October 10, 2009

Risk/Benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.

Hemoglobin. 2009;33(5):386-97.

Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A.

Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus.

Keywords: oxidative stress, brain, heart, liver, kidneys, classical antioxidants, deferiprone, mobilizing labile iron and copper, free radicals, high therapeutic index, tissue penetration, rapid iron binding, clearance, iron complex, toxicity, cardiomyopathy, thalassemia, diabetic nephropathy, glomerulonephritis, kidney disease, Friedreich's Ataxia, Fanconi Anemia, deferoxamine (DFO), deferasirox (DFRA).

Thursday, October 8, 2009

Friedreich ataxia: a computational dynamic model of the key proteins involved in the yeast Fe–S cluster biogenesis

Friedreich ataxia: a computational dynamic model of the key proteins involved in the yeast Fe–S cluster biogenesis
New Biotechnology
Volume 25, Supplement 1, September 2009, Pages S342-S343
Abstracts of the 14th European Congress on BiotechnologyBarcelona, Spain 13–16 September, 2009

I. Amela1, J. Cedano1, P. Delicado2 and E. Querol1

1Universitat Autònoma de Barcelona, Bellatera - Barcelona, Spain

2Universitat Politècnica de Catalunya, Barcelona, Spain

Characterizing gait, locomotor status, and disease severity in children and adolescents with friedreich ataxia.

J Neurol Phys Ther. 2009 Sep;33(3):144-9.

Croarkin E, Maring J, Pfalzer L, Harris-Love M, Siegel K, Diprospero N.
National Institutes of Health (E.C., K.S.), Bethesda, MD; George Washington University, Physical Therapy Program (J.M., M.H.L.), Washington, DC; University of Michigan School of Health Related Professions and Studies (L.P.), Ann Arbor, Michigan; and National Institute of Neurological Disorders and Stroke (N.D.P.), Bethesda, Maryland.

KEYWORDS: gait parameters, children, adolescents, Friedreich ataxia (FA), disease severity, Friedreich Ataxia Rating Scale (FARS), walk.

Mystery About Proteins That Package The Genome Solved

Florida State University. "Mystery About Proteins That Package The Genome Solved." ScienceDaily 8 October 2009

Keywords: regulate gene expression, histones, packaging DNA, genes are turned on or off,

Wednesday, October 7, 2009

Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy

Nature Medicine 15, 1215 - 1218 (2009)
Published online: 13 September 2009 | doi:10.1038/nm.2025

Yong Hong Chen1, Michael Chang2 & Beverly L Davidson1,3

  1. Department of Internal Medicine, Iowa City, Iowa, USA.
  2. Departments of Molecular Physiology & Biophysics, Iowa City, Iowa, USA.
  3. Department of Neurology, University of Iowa, Iowa City, Iowa, USA.

Keywors: Brain vasculature,  neural cells, microvessel,  enzyme replacement therapy, central nervous system (CNS), endothelia,  neurons,  glia, adeno-associated virus (AAV),  biodistribution.

Glutaredoxins: roles in iron homeostasis

Trends in Biochemical Sciences
Article in Press,
 
Nicolas Rouhier1, , Jérémy Couturier1, Michael K. Johnson2 and Jean-Pierre Jacquot1


1Unité Mixte de Recherches 1136 INRA Nancy University, Interactions Arbres Microorganismes, IFR 110 EFABA, Faculté des Sciences, BP 239 54506, Vandoeuvre Cedex, France
2Department of Chemistry and Center for Metalloenzyme Studies, University of Georgia, Athens, GA 30602, USA


Available online 5 October 2009.

Sunday, October 4, 2009

Mitochondria - A neglected drug target.

Curr Opin Investig Drugs. 2009 Oct;10(10):1022-4.Links

Murphy MP.
Medical Research Council Mitochondrial Biology Unit, Wellcome Trust/MRC Building, Hills Road, Cambridge, CB2 0XY, UK. mpm@mrc-mbu.cam.ac.uk.

Saturday, October 3, 2009

No Link Between Suicide and Stop-Smoking Drugs

By Kristina Fiore, Staff Writer, MedPage Today
Published: October 02, 2009
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco. 


Keywords:  varenicline (Chantix)

Friday, October 2, 2009

Diverse effects in Friedreich's ataxia place PGC-1alpha center-stage.

Clin Genet. 2009 Oct;76(4):345-7
Metzler M.

Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, Vancouver, BC, Canada. martina@cmmt.ubc.ca

Monday, September 28, 2009

Biophysical Characterization of the Iron in Mitochondria from Atm1p-Depleted Saccharomyces cerevisiae

Biochemistry, Article ASAP DOI: 10.1021/bi901110n
Publication Date (Web): September 17, 2009
 
Ren Miao, Hansoo Kim, Uma Mahendra Kumar Koppolu, E. Ann Ellis, Robert A. Scott and Paul A. Lindahl*

‡ Department of Chemistry § Microscopy and Imaging Center,
Department of Biochemistry and Biophysics
Texas A&M University, College Station, Texas 77843-3255
Department of Chemistry, University of Georgia, Athens, Georgia 30602-2556

Keywords: Atm1p, ABC transporter, mitochondrial inner membrane, cytosol, cellular iron metabolism, cytosolic Fe/S cluster assembly, mitochondrial Fe/S cluster assembly,  Mssbauer spectroscopy, EPR, electronic absorption spectroscopy, X-ray absorption spectroscopy, and electron microscopy, aerobically grown cells, iron(III) phosphate nanoparticles,  yeast frataxin Yfh1p-deleted, yeast ferredoxin Yah1p-depleted,  Atm1p-depleted, nonheme Fe(II) ions, oxidative damage,  cytosolic Fe/S cluster assembly,  oxygen.

Saturday, September 26, 2009

Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich's Ataxia Gene Silencing

Chemistry & Biology, Volume 16, Issue 9, 980-989, 25 September 2009
Chunping Xu1, Elisabetta Soragni1, C. James Chou1, David Herman1, Heather L. Plasterer2, James R. Rusche2 and Joel M. Gottesfeld1,

1 Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
2 Repligen Corporation, Waltham, MA 02453, USA

Keywords: pimelic diphenylamide histone deacetylase (HDAC) inhibitors, Friedreich's ataxia (FRDA), Huntington's disease, HDAC3.

Neurophysiological evaluation in children with Friedreich's ataxia.

Early Hum Dev. 2009 Sep 21.

Sival DA, du Marchie Sarvaas GJ, Brouwer OF, Uges DR, Verschuuren-Bemelmans CC, Maurits NM, Brunt ER, van der Hoeven JH.


Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, The Netherlands.

Keywords:  Friedreich's ataxia (FRDA children), ICARS, idebenone treatment, longitudinal neurophysiological parameters,   two-year study,  period, cardiomyopathy (6-18years), sensory evoked potentials (SEPs), F response, peripheral nerve conduction , dynamometry, SEPs , peroneal nerve conduction velocity,  not substantiate neurologic improvement.